MITRIS RESILIA干式二尖瓣瓣膜

Search documents
二尖瓣疾病高发!这些症状或是“心脏阀门”预警
Zhong Guo Xin Wen Wang· 2025-05-01 03:11
Group 1 - The prevalence of heart valve diseases in China is increasing, with approximately 25 million people affected, making it the third most common cardiovascular disease after coronary heart disease and hypertension [1] - The most common type of heart valve disease is mitral valve disease, which is particularly significant due to the high pressure it endures [1] - Aging and modern lifestyle factors contribute to the rising incidence of heart valve diseases, leading to a younger demographic being affected [1] Group 2 - Treatment for valve diseases typically requires surgical intervention, either through repair or replacement, as medications alone are insufficient [2] - Advances in technology have led to minimally invasive procedures for mitral valve treatment, reducing surgical trauma [2] - The introduction of new products, such as the MITRIS RESILIA dry mitral valve, enhances treatment options and durability for patients [2] Group 3 - Improved diagnostic capabilities, particularly the widespread use of echocardiography, allow for early detection of valve diseases even before symptoms appear [3] - Regular health check-ups and screenings are essential for early diagnosis and management of heart valve conditions [3]
新式干式二尖瓣瓣膜在华上市
Xin Jing Bao· 2025-04-27 10:05
Group 1 - Edward Lifesciences announced the launch of the MITRIS RESILIA valve in China, which utilizes RESILIA technology for enhanced durability and offers a sustainable solution for patients requiring mitral valve replacement [1] - The MITRIS RESILIA valve is the first surgical bioprosthetic mitral valve to adopt the RESILIA fully enclosed anti-calcification technology, providing a new management solution for patients in China [1][2] - The valve has also received regulatory approval in the United States, Japan, and Canada, indicating its global market acceptance [1] Group 2 - The prevalence of cardiovascular diseases, particularly heart valve diseases, is increasing in China due to an aging population, making it the third most common cardiovascular condition after coronary heart disease and hypertension [2] - Surgical replacement remains the most widely used treatment for mitral valve diseases, with a trend towards less invasive, more durable, and personalized approaches [2] - The demand for minimally invasive surgical techniques is rising, as they reduce surgical trauma and improve patient outcomes [2] Group 3 - The MITRIS RESILIA valve features innovative RESILIA tissue processing technology that enhances valve durability by sealing the sources of calcification [3] - The valve's soft suture ring and low-profile design facilitate easier implantation, making it suitable for minimally invasive surgeries [3] - The valve's large opening design allows for future "valve-in-valve" interventions, ensuring a comprehensive solution for patients throughout their treatment journey [3]